Staphylococcus epidermidis: emerging resistance and need for alternative agents

Area of Science:

• Microbiology
• Infectious Diseases
• Clinical Medicine

Background:

• Coagulase-negative staphylococci (CoNS), once dismissed as contaminants, are now significant causes of nosocomial bloodstream infections.
• Increasing multidrug resistance in CoNS strains complicates diagnosis and treatment, distinguishing true infections from contaminants.
• Emerging resistance to quinolones (e.g., ciprofloxacin) and tolerance/resistance to vancomycin are critical concerns.

Purpose of the Study:

• To highlight the evolving role of CoNS as pathogens in hospital-acquired infections.
• To discuss the challenges posed by multidrug resistance and biofilm formation in Staphylococcus epidermidis infections.
• To review alternative therapeutic agents for device-related and glycopeptide-tolerant CoNS infections.

Main Methods:

• Literature review of recent studies on CoNS epidemiology and antimicrobial resistance.
• Analysis of clinical data on nosocomial bloodstream infections caused by CoNS.
• Evaluation of emerging resistance patterns, including quinolone and vancomycin resistance.
• Assessment of biofilm-associated antimicrobial tolerance in S. epidermidis.
• Review of proposed alternative antimicrobial agents.

Main Results:

• CoNS are a leading cause of nosocomial bloodstream infections, challenging previous assumptions.
• Significant resistance to ciprofloxacin and emerging tolerance/resistance to vancomycin have been documented.
• Vancomycin and other glycopeptides show reduced efficacy against S. epidermidis in biofilms.
• Alternative agents like minocycline, rifampin, quinupristin/dalfopristin, and oxazolidinones show promise.

Conclusions:

• Staphylococcus epidermidis and other CoNS are significant pathogens in healthcare settings.
• Antimicrobial resistance and biofilm formation necessitate novel treatment strategies.
• Alternative antibiotics are crucial for managing device-related and resistant CoNS infections.